SC 106

Drug Profile

SC 106

Latest Information Update: 04 Jul 2000

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Scotia Holdings [CEASED]
  • Class Anti-inflammatories; Antirheumatics
  • Mechanism of Action Leukotriene receptor antagonists; Prostaglandin synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 04 Jul 2000 Discontinued-II for Rheumatoid arthritis in United Kingdom (PO)
  • 11 Jun 1997 Phase-II clinical trials for Rheumatoid arthritis in United Kingdom (PO)
  • 02 Oct 1996 SC 106 is to be out-licensed by Scotia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top